Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Uber Technologies Inc UBER

Alternate Symbol(s):  N.UBER

Uber Technologies, Inc. is a technology company, which develops and operates proprietary technology applications supporting a variety of offerings on its platform (Platform(s)). The Company connects consumers (Rider(s)) with independent providers of ride services (Mobility Driver(s)) for ride sharing services and connects Riders and other consumers (Eater(s)) with restaurants, grocers and other stores with delivery service providers (Couriers) for meal preparation, grocery and other delivery services. The Company also connects consumers with public transportation networks. It also connects shippers with carriers in the freight industry. It is also developing technologies designed to provide new solutions to solve everyday problems. Its technology is available in approximately 70 countries around the world, principally in the United States and Canada, Latin America, Europe (excluding Russia), the Middle East, Africa, and Asia (excluding China and Southeast Asia).


NYSE:UBER - Post by User

Post by ScarletteBourneon Jun 03, 2022 3:41am
121 Views
Post# 34728643

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>